What is it?
Identity matters
1Oxiracetam, also known by the research code ISF-2522, is a synthetic racetam. Its chemical identity is distinct from piracetam, and an identifier in a substance database is not approval of a finished consumer product.
Older positive findings were small
2A 1992 placebo-controlled study enrolled 65 older adults with degenerative, multi-infarct or mixed dementia. Some cognitive tests and a quality-of-life scale favored oxiracetam over 12 weeks. Two participants receiving oxiracetam withdrew for poor tolerability. This is condition-specific evidence, not a healthy-adult performance result.
A conflicting Alzheimer study
3Another double-blind study in 24 patients with probable Alzheimer's disease found no cognitive improvement on its neuropsychological battery. The conflict with positive small studies argues against a general memory-enhancement claim.
The brain-injury trial is now complete
10The 2025 LOCATE trial enrolled 590 people after mild-to-moderate brain injury. It compared intravenous L-oxiracetam, racemic oxiracetam and placebo for 14 days. L-oxiracetam favored the primary cognitive score at day 90 versus both comparators, but many secondary outcomes were null and about one quarter did not complete that assessment. This is not evidence for an equivalent oral powder regimen.
A larger oral trial found no cognitive advantage
9In a 2025 post-stroke trial, 500 participants were randomized and 457 completed follow-up. Neither the MMSE nor CDR-SB cognitive endpoint favored oxiracetam. Exploratory imaging findings did not overturn those null results. Adverse events were numerically more frequent with oxiracetam, but the difference was not statistically significant and investigators identified no clinically relevant attributable signal.
Names, aliases and forms
Mechanisms of action
Mechanistic proposals remain indirect
4Racetam research discusses cholinergic signaling and neuronal membrane processes, but much of the mechanistic work is preclinical. A plausible pathway cannot establish a useful cognitive effect, a personal dose or superiority over another racetam.
Potential effects and evidence map
Grade C reflects inconsistent human cognitive findings and limited relevance to healthy-adult enhancement. Older small dementia studies conflict, a large oral post-stroke trial was negative, and recent positive brain-injury findings used intravenous preparations. Neither a racetam label nor measurable blood exposure proves better everyday cognition.
Typical dosages and timing
The study used 800 mg twice daily for 36 weeks and found no advantage on either cognitive coprimary outcome. This is research context, not a validated dose for healthy-adult enhancement or a suggested cycle.
Timing & effect horizon
A small single-dose study in eight healthy Japanese volunteers found plasma peaks around one hour and terminal half-lives of 5.7-9.8 hours across fasting dose groups. Only six received active drug. These measurements do not establish when better cognition starts, how long it lasts or when to redose.
Safety, side effects and risk profile
Healthy-user efficacy and long-term safety remain incompletely characterized.
Oral postmarketing reports include dizziness, tremor and seizure-like events.
The oral label calls for dose reduction with excitation or sleep disturbance.
The oral label says pregnancy and breastfeeding use should be avoided.
China's oral-label update includes allergy-like reactions, seizure-like events, arrhythmias and abnormal liver or kidney function among postmarketing reports. It gives no incidence or healthy-user causal estimate. Injection-only shock warnings should not be transferred to an oral powder.
Interactions and cautions
The cited literature does not validate combining oxiracetam with other racetams, stimulants or choline products. A proposed cholinergic mechanism is not evidence that choline is required, and sparse interaction reporting does not establish compatibility with prescription medicines.
Legal and regulatory status
As reviewed October 12, 2026, a June 2022 United States Department of Justice release includes oxiracetam among the unapproved and misbranded drugs in that case. Online availability or a research label is not FDA approval. This historical case is not a worldwide possession rule; check the destination market and exact product category.
How it compares
The L-enantiomer is one stereochemical component of racemic oxiracetam. The recent clinical comparison used different intravenous preparations and doses under inpatient care. Do not divide a trial dose or copy its results onto an unspecified retail powder; verify the actual identity and route first.
Practical buying and quality notes
- For single-ingredient powder, compare the package total and price per gram. Fifty grams is 50,000 mg of listed powder, not 50,000 mg per serving. Capsules require their declared oxiracetam amount as well as the count; sample packs and blends are not equivalent units.1
- Check whether the certificate identifies oxiracetam, matches the package lot, names the analytical method and reports relevant impurities. The 2022 U.S. enforcement case included misleading testing claims; it is not evidence of misconduct by today's listed vendors. A purity percentage cannot establish clinical suitability.11
FAQ
What oxiracetam dose is supported for healthy adults?
9No dose is validated for everyday cognitive enhancement in healthy adults. The displayed daily amount belongs to a clinical study with negative primary results. Trial dosing is not a powder-measuring instruction, and increasing exposure does not establish greater benefit.
How long does oxiracetam last, and should it be cycled?
7Plasma elimination is measurable, but a useful period of enhanced cognition and an evidence-based cycling schedule are not established. The study window is not a recommended cycle. Kidney function also changes elimination, so an average The time for blood levels to fall by half during the final elimination phase.Source cannot specify a personal redosing interval.
References
- PubChem Compound Summary for Oxiracetam, CID 4626.
- Bottini G, Vallar G, Cappa S, Monza GC, Scarpini E. Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurol Scand. 1992.
- Green RC, Goldstein FC, Auchus AP, Presley R, Clark WS. Treatment trial of oxiracetam in Alzheimer's disease. Arch Neurol. 1992.
- Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010.
- Nakashima M, et al. Phase I Study of CT-848 (The 1st Report): single oral administration. Japanese Journal of Clinical Pharmacology and Therapeutics. 1991;22:501-510.
- Nakashima M, Kanamaru M, Morishita D, Uno K. Phase I Study of CT-848 (The 2nd Report): multiple oral administration. Japanese Journal of Clinical Pharmacology and Therapeutics. 1991;22:511-520.
- Lecaillon JB, et al. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose. Eur J Drug Metab Pharmacokinet. 1990;15:231-237.
- China National Medical Products Administration. Announcement No. 84 of 2021, Annex 2: revisions to oral oxiracetam product information. June 22, 2021.
- Lim JS, et al. Oxiracetam and physical activity in preventing cognitive decline after stroke: a multicenter, randomized controlled trial. European Stroke Journal. Published online July 27, 2025.
- Liu T, et al. Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. Signal Transduction and Targeted Therapy. 2025;10:401.
- U.S. Department of Justice. Fort Collins Couple Sentenced to Federal Prison for Illegally Selling Unapproved Drugs. June 10, 2022.